myTomorrows Secures $29M to Grow AI Platform for Patient Access to Experimental Treatments

Health technology firm myTomorrows, which is revolutionizing patient access to experimental treatments, has secured $29 million in growth equity funding from Avego. This funding will accelerate the company’s worldwide growth and advance its AI-powered platform, designed to seamlessly connect patients, doctors, clinical trial sites, and BioPharma partners within a unified ecosystem.

With over 300 million patients globally living without approved treatment options for their conditions, myTomorrows is addressing a critical gap in healthcare: connecting patients with promising therapies still in clinical development or awaiting regulatory approval. The company’s platform acts as a digital bridge between cutting-edge research and those in need, enabling individuals to find and navigate previously hard-to-access clinical trials and expanded access programs.

Expanding Access Through AI Innovation

Central to myTomorrows’ mission is its sophisticated AI infrastructure, designed to make healthcare navigation smarter, more transparent, and fair. The company’s algorithms continuously analyze data from thousands of clinical trials and regulatory documents to identify potential matches between patients and emerging treatments. This method significantly reduces the time physicians spend searching for relevant opportunities while improving the precision of recommendations.

The new capital will help myTomorrows enhance these capabilities—refining its machine learning models to simplify physician referrals, provide deeper regulatory insights, and strengthen evidence generation for BioPharma collaborators. The platform’s AI tools not only expedite access but also assist pharmaceutical companies in identifying trial participation gaps, thereby accelerating the overall pace of clinical research.

“Our mission has always been to ensure every patient, no matter where they live, has a genuine opportunity to benefit from tomorrow’s treatments,” stated Michel van Harten, CEO of myTomorrows. “With Avego’s financial backing and deep life sciences expertise, we can scale our AI systems worldwide, enrich our data-driven insights, and ultimately help more patients gain access to promising experimental therapies.”

James Flexner, Managing Partner at Avego, shared this perspective, stating, “myTomorrows is uniquely equipped to break down barriers for patients and providers while serving as a vital partner to BioPharma. Their AI-driven model is redefining the intersection of clinical access and real-world evidence.”

A Worldwide Network Empowering Patients and Doctors

Since its establishment in 2012, myTomorrows has enabled more than 16,900 patients across 133 countries to access experimental treatments that would otherwise be unavailable. Its AI-enabled platform combines personalized human support with automated data analysis to connect patients with the most appropriate programs, whether they involve clinical trials or expanded access pathways.

For physicians, the platform functions as a decision-support resource, simplifying a traditionally complex and fragmented process. For BioPharma companies, myTomorrows offers recruitment and data management services that enhance trial efficiency and adherence. The system also provides real-time visibility for trial sites, ensuring smooth coordination among participants, clinicians, and sponsors.

Dr. Ronald Brus, the company’s founder and board member, highlighted the long-term vision: “When we launched myTomorrows, we envisioned a world where patients could easily connect with medical innovation, and where data from these experiences could meaningfully advance drug development. This new investment represents a pivotal step—transitioning from potential to tangible global impact.”

AI as a Catalyst for Healthcare Change

Beyond its immediate clinical uses, myTomorrows embodies a wider movement toward AI-supported healthcare ecosystems that link diverse stakeholders—from researchers and regulators to hospitals and patients—through shared intelligence. The platform collects real-world data on patient outcomes, which can help shape regulatory choices, direct R&D efforts, and improve the design of future clinical studies.

As digital health and conventional medicine increasingly overlap, this kind of AI-enabled transparency and collaboration could transform how new treatments reach the market. Rather than waiting years for novel drugs to complete approval processes, patients could obtain controlled access to promising therapies while data continues to support ongoing clinical validation.

This model suggests a future where AI serves as the connective framework of global healthcare—enabling fluid, data-guided collaboration among patients, clinicians, and pharmaceutical developers. For millions confronting severe or rare illnesses, this future may arrive not in decades, but in just a few years.

“AI is no longer just an auxiliary tool in healthcare,” added van Harten. “It is becoming the cornerstone of how we link medical innovation with human need. We are committed to preventing promising treatments from remaining unused when they could be helping patients.”

Looking Forward

Supported by Avego and over a decade of foundational work, myTomorrows is now entering its most ambitious phase—constructing the infrastructure needed for AI-driven access to experimental medicine on a global scale. By prioritizing responsible data practices, transparent patient engagement, and collaboration with BioPharma leaders, the company stands at the vanguard of the next generation in healthcare delivery.

If successful, its approach could reshape how the world perceives drug development—not as a linear pathway ending with regulatory approval, but as an adaptive, data-enriched ecosystem in which AI and human knowledge collaborate to ensure breakthrough treatments reach patients precisely when needed.